


4Q & Full Year 2025 Financial Results

February 10, 2026

Overview

DuPont de Nemours, Inc. (“DuPont”) completed the previously announced separation of its Electronics business (the “Electronics Separation”) into an independent public company, Qnity Electronics, Inc. (“Qnity”), by way of the distribution to DuPont's stockholders of record as of October 22, 2025 of all the issued and outstanding common stock of Qnity on November 1, 2025 (the “Qnity Distribution”). As a result, beginning in the fourth quarter of 2025, the financial results of the divested Electronics business are reflected in DuPont's Consolidated Financial Statements as discontinued operations, along with comparative periods.

On August 29, 2025, DuPont announced a definitive agreement to sell the aramids business (the “Aramids Divestiture”) to Arclin a portfolio company of a TJC LP, (“TJC”) affiliate, in return for pre-tax cash proceeds of approximately $1.2 billion, subject to customary transaction adjustments, a note from TJC in the principal amount of $300 million and a minority equity interest (the “Equity Consideration”) valued at $325 million in the future Arclin holding company that will hold the Arclin global materials business and the aramids business being divested. The transaction is expected to close around the end of the first quarter 2026, subject to customary closing conditions and receipt of regulatory approvals. As a result, beginning in the third quarter of 2025, the financial results of the aramids business being divested are reflected in DuPont's Consolidated Financial Statements as discontinued operations, along with comparative periods.

Cautionary Statement Regarding Forward-looking Statements

Certain statements in this release may be considered forward-looking statements, within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements often contain words such as “expect”, “anticipate”, “intend”, “plan”, “believe”, “seek”, “see”, “will”, “would”, “target”, “outlook”, “stabilization”, “confident”, “preliminary”, “initial”, “continue”, “may”, “could”, “project”, “estimate”, “forecast” and similar expressions and variations or negatives of these words. All statements, other than statements of historical fact, are forward-looking statements. Forward-looking statements address matters that are, to varying degrees, uncertain and subject to risks, uncertainties, and assumptions, many of which are beyond DuPont's control, that could cause actual results to differ materially from those expressed in any forward-looking statements.

Forward-looking statements are not guarantees of future results. Some of the important factors that could cause DuPont's actual results to differ materially from those projected in any such forward-looking statements include, but are not limited to (i) the ability to realize the intended benefits of the Electronics Separation and Qnity Distribution, including achievement of the intended tax treatment; contractual allocation to, and assumption by Qnity of certain liabilities, including certain legacy liabilities with respect to PFAS; and the possibility of disputes, litigation or unanticipated costs in connection with the Electronics Separation and Distribution; (ii) the ability to timely effect, if at all, the Aramids Divestiture and the impact on DuPont’s balance sheet, financial condition and future results of operations; (iii) risks and costs related to the impact of the arrangement to share future eligible PFAS costs by and among DuPont, Corteva and Chemours, including the outcome of pending or future litigation related to PFAS or PFOA, which includes personal injury claims and natural resource damages claims; the extent and cost of ongoing and potential future remediation obligations; and changes in laws and regulations applicable to PFAS chemicals; (iv) the failure to realize expected benefits and effectively manage and achieve anticipated synergies and operational efficiencies in connection with the Electronics Separation, the Aramids Divestiture and completed and future, if any, divestitures, mergers, acquisitions, and other portfolio management, productivity and infrastructure actions; (v) risks and uncertainties that are outside the Company’s control but adversely impact the overall environment in which DuPont, its customers and/or its suppliers operate, including changes in economic, political, regulatory, international trade, geopolitical, military conflicts, capital markets and other external conditions, including pandemics and responsive actions, as well as natural and other disasters or weather-related events; (vi) the ability to offset increases in cost of inputs, including raw materials, energy and logistics; (vii) the risks and uncertainties associated with continuing or expanding trade disputes or restrictions and responsive actions, new or increased tariffs or export controls including on exports to China of U.S.-regulated products and technology; (viii) other risks to DuPont’s business and operations, including the risk of impairment; (ix) risks and uncertainties in connection with completing the $2 billion share buyback authorization DuPont announced on November 3, 2025, including timeline, associated costs and the possibility that the authorization may be suspended or discontinued prior to completion; and (x) other risk factors discussed in DuPont’s most recent annual report on Form 10-K, and subsequent quarterly reports on Form 10-Q and current reports on Form 8-K filed with the U.S. Securities and Exchange Commission.

Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business or supply chain disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on DuPont’s consolidated financial condition, results of operations, credit rating or liquidity. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. DuPont assumes no obligation to publicly provide revisions or updates to any forward-looking statements whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

2025 Highlights

FY 2025 Financials

- Organic sales growth driven by strength in healthcare and water end-markets
- Strong operational execution and productivity drove EBITDA growth and margin expansion
- Strong free cash flow generation and conversion
- Executed $500 million ASR in the fourth quarter

Operational Highlights

- Successful separation of Qnity™
- Build out of leadership team for the new DuPont
- Enhanced performance-based culture, emphasizing growth and continuous improvement
- Building a robust business system to continue driving excellence and consistency
- Set clear and robust medium-term financial targets

2026 Strategic Priorities

Drive Organic Growth	• Streamlined portfolio, well-positioned in **high-growth secular markets** • **Innovation**: launched >125 new products in 2025 to support organic growth • AI investments to **accelerate demand generation**
Build a Robust Business System	• Driving **continuous improvement**; standard set of managing processes • **Commercial excellence**: centered on demand generation and pipeline discipline • **Operational excellence**: refreshed KPIs aimed at driving productivity
Deploy Balanced Capital Allocation	• Committed to a strong balance sheet, **<2x net leverage** • Consistent **quarterly dividends** in line with targeted payout ratio • $1.5B remaining under **share repurchase authorization** • M&A strategy focused on **high-growth secular markets**

Deliver consistent financial performance

Note: Dividends and timing of share repurchases are subject to Board approval.

FY 2026 Financial Guidance

~3%
Organic Net Sales Growth

60 – 80 bps
Op. EBITDA Margin Expansion

$2.25 - $2.30
Adjusted EPS

>90%
Free Cash Flow Conversion

2026 Macro Trend Assumptions

Global Surgical Procedures	Mid-single digit growth
Global Water Intelligence	Mid-single digit growth; Low-single digit growth in China
Global GDP	>2% led by growth in Asia
Industrial Production	<2%, growth in Asia offset by weakness in US/Canada
Global Autobuilds	About flat, weaker in US and Europe
U.S Construction	About flat

Note: Operating EBITDA margin expansion is on a reported basis. FY 2025 operating EBITDA margin was 23.8%.

4Q 2025 Financial Highlights

Sales Drivers

Net Sales
$1.7 billion
Flat YoY

Organic Sales
-1% [as reported]
+1% [ex-timing[1]]

Organic Sales:
Growth in healthcare and water end-markets was more than offset by continued softness in construction

Currency: +1%

Portfolio: flat

Organic Sales by Segment:
Healthcare & Water Technologies +3%
Diversified Industrials -4%

Organic Sales by Region:
EMEA +2%
U.S./Canada flat
Asia Pacific -2%

Profitability & Cash Flow

Operating EBITDA
$409 million

- Up 4% YoY on favorable mix and cost productivity, partially offset by growth investments
- Margin +80 bps to 24.2%

Adjusted EPS
$0.46/share

- +18% on higher segment earnings and lower interest expense, partially offset by a higher tax rate

Transaction-Adjusted FCF[2]
$228 million

- Transaction-adjusted free cash flow (FCF) from continuing operations of $228 million and related conversion of 118%

[1] Fourth quarter net sales included an approximately $30 million headwind from the order timing shift into the third quarter related to system cut-over activities in advance of the planned electronics separation.
[2] Cash provided by operating activities from continuing operations of $87 million, CapEx of $87 million and separation-related transaction cost and other payments of $228 million resulted in transaction-adjusted free cash flow (FCF) from continuing operations of $228 million.

4Q 2025 Adjusted EPS Bridge



DUPONT

Healthcare & Water Technologies

4Q Net Sales



4Q Operating EBITDA



4Q 2025 YoY Highlights

Organic Sales by Line of Business[1]

- **Healthcare Technologies** Sales up mid-single digits on an organic basis on broad-based growth led by medical packaging and medical devices
- **Water Technologies** Sales up low-single digits on an organic basis primarily due to strength in industrial water markets, partially offset by order-timing headwinds

---

- Operating EBITDA increased on organic growth and productivity, partially offset by growth investments
- Operating EBITDA margin of 31.1% was flat

DUPONT

[1] Effective in the fourth quarter of 2025, following the separation of the Electronics business on November 1, 2025, the Company made changes to its management and reporting structure creating two new reportable segments: Healthcare & Water Technologies and Diversified Industrials.

Diversified Industrials

4Q Net Sales



4Q Operating EBITDA



4Q 2025 YoY Highlights




Organic Sales by Line of Business[1]

- **Building Technologies** Sales down high-single digits on an organic basis from ongoing weakness in construction markets
- **Industrial Technologies** Sales down low-single digits on an organic basis as strength in aerospace was offset by weakness in printing and packaging and order-timing headwinds

---

- Operating EBITDA increased on favorable mix and cost productivity
- Operating EBITDA margin of 22.6% increased 110 basis points

[1] Effective in the fourth quarter of 2025, following the separation of the Electronics business on November 1, 2025, the Company made changes to its management and reporting structure creating two new reportable segments: Healthcare & Water Technologies and Diversified Industrials.

1Q and FY 2026 Guidance

Key Metrics

	1Q 2026	FY 2026
Net Sales	**~$1.67 billion**	**$7.075 - $7.135 billion**
Operating EBITDA	**~$395 million**	**$1.725 - $1.755 billion**
Adjusted EPS	**~$0.48**	**$2.25 - $2.30**

Key Assumptions

- **1Q'26:** Assumes ~2 percent organic sales growth YoY, along with foreign currency tailwinds of ~2 percent
- **FY'26:** Assumes ~3 percent organic sales growth YoY, along with foreign currency tailwinds of ~1 percent

Note: Segment expectations and additional modeling guidance included on slides 15-16, respectively.

Appendix

4Q 2025 Net Sales Bridge



FY 2025 Financial Highlights

Sales Drivers

Net Sales
$6.8 billion
+2%

Organic Sales
+2%

Organic Sales:
Growth in healthcare and water end-markets, partially offset by softness in construction markets

Currency: flat

Portfolio: flat

Organic Sales by Segment:
Healthcare & Water Technologies +7%
Diversified Industrials -2%

Organic Sales by Region:
Asia Pacific +4%
EMEA +3%
U.S./Canada +1%

Profitability & Cash Flow

Operating EBITDA
$1.6 billion

- Up 6% YoY on organic growth and productivity, partially offset by growth investments
- Margin +100 bps to 23.8%

Adjusted EPS
$1.68/share

- +16% on higher segment earnings and lower interest expense

Transaction-Adjusted FCF[1]
$689 million

- Transaction-adjusted free cash flow (FCF) from continuing operations of $689 million and related conversion of 98%

DUPONT

[1] Cash provided by operating activities from continuing operations of $560 million, CapEx of $333 million and separation-related transaction cost and other payments of $462 million resulted in transaction-adjusted free cash flow (FCF) from continuing operations of $689 million.

FY 2025 Net Sales Bridge



Note: Portfolio primarily reflects sales activity associated with the acquisition of Donatelle which closed July 28, 2024, offset by the exit of a Tedlar® PV product line beginning in 4Q24.

2026 Segment Expectations

Healthcare & Water Technologies






1Q2026

- Expect low to mid-single digit organic sales growth year-over-year
- Continued growth in healthcare and water end-markets

FY2026

- Expect mid-single digit organic sales growth year-over-year
- Broad-based strength in Healthcare driven by medical packaging and medical devices; Growth in Water led by strength in industrial and municipal markets

Diversified Industrials





1Q2026

- Expect slight organic sales growth year-over-year
- Growth in aerospace and automotive end-markets partially offset by continued softness in construction end-markets

FY2026

- Expect low-single digit organic sales growth year-over-year
- Industrial Technologies growth driven by strength in aerospace and demand recovery in industrial markets; Building Technologies about flat on stabilization in construction end-markets

Additional Modeling Guidance

Additional Modeling Guidance	
Base Tax Rate	~26% - 1Q 26 ~25%-26% - FY 26
D&A	~$625 million, pre-tax
Depreciation	~$350 million, pre-tax
Intangible Amortization	~$275 million, pre-tax
Interest Expense, net	~$110 million, pre-tax
Exchange Losses	~$10-$15 million, after-tax
Share count – diluted Weighted Average	~410 million
Corporate[1]	~$33 million – 1Q 26 ~$115-$120 million – FY 26

[1] Includes results related to the Company's non-controlling equity interest acquired as part of the Delrin® (19.9%) divestiture as well as stranded costs.

Medium-term targets
Expected performance from FY2025 – FY2028

Organic Growth Driving innovation and capitalizing on long-term market tailwinds	**3 – 4% CAGR** Organic Net Sales
Margin Expansion Sustaining strong margins through continuous improvement and a high-growth asset mix	**150 – 200bps Improvement** Op. EBITDA Margin
Earnings Per Share Growth Growth and margin expansion translating into sustained value creation	**8-10%** Adjusted EPS Growth CAGR
Free Cash Flow Generation Strong cash flow generation through EBITDA growth and working capital improvement	**>90%** Free Cash Flow Conversion

Note: Medium-term targets represent expected performance from FY2025 – FY 2028. Deployment of excess FCF is incremental to 2028 targets.

Non-GAAP Financial Measures:

Unless otherwise indicated, all financial metrics presented reflect continuing operations only.

This communication includes information that does not conform to accounting principles generally accepted in the United States of America ("U.S. GAAP") and are considered non-GAAP measures. Management uses these measures internally for planning, forecasting and evaluating the performance of the Company, including allocating resources. DuPont's management believes these non-GAAP financial measures are useful to investors because they provide additional information related to the ongoing performance of DuPont to offer a more meaningful comparison related to future results of operations. These non-GAAP financial measures supplement disclosures prepared in accordance with U.S. GAAP, and should not be viewed as an alternative to U.S. GAAP. Furthermore, such non-GAAP measures may not be consistent with similar measures provided or used by other companies. Reconciliations for these Non-GAAP measures to U.S. GAAP are provided in the Selected Financial Information and Non-GAAP Measures starting on page 15. Non-GAAP measures included in this communication are defined below. The Company has not provided forward-looking U.S. GAAP financial measures or a reconciliation of forward-looking non-GAAP financial measures to the most comparable U.S. GAAP financial measures on a forward-looking basis because the Company is unable to predict with reasonable certainty the ultimate outcome of certain future events. These events include, among others, the impact of portfolio changes, including asset sales, mergers, acquisitions, and divestitures; contingent liabilities related to litigation, environmental and indemnifications matters; impairments and discrete tax items. These items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP results for the guidance period.

Key Terms

Significant Items

Significant items are items that arise outside the ordinary course of business for the Company, and beginning in the first quarter 2025, includes items for nonconsolidated affiliates, that the Company's management believes may cause misinterpretation of underlying business and investment performance, both historical and future, based on a combination of some or all of the item's size, unusual nature and infrequent occurrence. Management classifies as significant items certain costs and expenses associated with integration and separation activities related to transformational acquisitions and divestitures as they are considered unrelated to ongoing business performance. Management believes the update to the definition of significant items to include those related to nonconsolidated affiliates reflects a more accurate measure of the ongoing performance of the investment. There were no significant items associated with nonconsolidated affiliates recorded for the three and twelve month periods ended December 31, 2025 and December 31, 2024.

Future Reimbursable Indirect Costs

Indirect costs, such as those related to corporate and shared service functions allocated to the separated Electronics business, the divested Delrin® business and the Aramids business, do not meet the criteria for discontinued operations and are reported within continuing operations in all respective periods presented. The Company has, is, will or expects to be reimbursed in accordance with the applicable transition service agreements ("TSAs") for the portion of indirect costs related to activities the Company is, will or expects to undertake on a transitional basis to support a) the divested Delrin® business, b) Qnity not beyond year end 2027 for services and 2040 for site leases and, c) the Aramids Business post the intended Aramids Divestiture, but not beyond 2028 (such indirect costs "Future Reimbursable Indirect Costs"). Services provided and costs reimbursed in accordance with the applicable TSAs include but are not limited to, costs associated with information technology services/support, product stewardship and regulatory support, facilities services, and shared property lease costs.

Future Reimbursable Indirect Costs do not meet the criteria for discontinued operations and therefore are included in both GAAP Net Income from Continuing Operations and in GAAP Cash provided by operating activities-continuing operations for all periods presented. Future Reimbursable Indirect Costs are excluded from Adjusted Earnings, Operating EBITDA and beginning in the fourth quarter 2025, from Transaction-Adjusted Free Cash Flow, each defined below. Such indirect costs that are not subject to future reimbursement are reported within continuing operations in Corporate & Other and are included within Adjusted Earnings, Operating EBITDA, and Cash provided by operating activities-continuing operations.

Corporate DDOB Remediation Costs

Corporate DDOB Remediation Costs are environmental remediation costs, including certain investigate, remediate and restoration costs, associated with discontinued or divested operations, businesses or product lines ("Corporate DDOB Remediation Costs"). Subsequent to the spin-off of Qnity and beginning with the fourth quarter of 2025, DDOB Remediation Costs are excluded from Adjusted Earnings and Operating EBITDA, as defined below, to provide better insight into the underlying business performance of the Company. This update was applied for all periods presented.

Non-GAAP Financial Measures Definitions

Organic Sales

Organic Sales is defined as net sales excluding the impacts of currency and portfolio.

Adjusted Earnings

Adjusted Earnings is defined as income from continuing operations excluding the after-tax impact of significant items, after-tax impact of amortization expense of intangibles, the after-tax impact of non-operating pension / other post employment benefits ("OPEB") credits / costs, Future Reimbursable Indirect Costs and Corporate DDOB Remediation Costs.

Adjusted Earnings is the numerator used in the calculation of Adjusted EPS, as well as the denominator in Adjusted Free Cash Flow Conversion.

Adjusted EPS

Adjusted EPS is defined as Adjusted Earnings per common share - diluted. Management estimates amortization expense in 2026 associated with intangibles to be about $270 million on a pre-tax basis, or approximately $0.50 per share.

Operating EBITDA, EBITDA Margin & Incremental Margin

The Company's measure of profit/loss for segment reporting purposes is Operating EBITDA as this is the manner in which the Company's chief operating decision maker ("CODM") assesses performance and allocates resources. The Company defines Operating EBITDA as earnings (i.e., "Income from continuing operations before income taxes") before interest, depreciation, amortization, non-operating pension / OPEB benefits / charges, and foreign exchange gains / losses, excluding Future Reimbursable Indirect Costs, Corporate DDOB Remediation Costs, and adjusted for significant items. Reconciliations of these measures are provided on the following pages.

Operating EBITDA Margin is defined as Operating EBITDA divided by Net Sales.

Incremental Margin is the change in Operating EBITDA divided by the change in Net Sales for the applicable period.

Adjusted Free Cash Flow & Adjusted Free Cash Flow Conversion

Adjusted Free Cash Flow is defined as cash provided by/used for operating activities from continuing operations less capital expenditures and excluding the impact of cash inflows/outflows that are unusual in nature and/or infrequent in occurrence that neither relate to the ordinary course of the Company's business nor reflect the Company's underlying business liquidity. As a result, Adjusted Free Cash Flow represents cash that is available to the Company, after investing in its asset base, to fund obligations using the Company's primary source of liquidity, cash provided by operating activities from continuing operations. Management believes Adjusted Free Cash Flow, even though it may be defined differently from other companies, is useful to investors, analysts and others to evaluate the Company's cash flow and financial performance, and it is an integral measure used in the Company's financial planning process. Management notes that there were no exclusions for items that are unusual in nature and/or infrequent in occurrence for the three and twelve-month periods ended December 31, 2025 and December 31, 2024.

Adjusted Free Cash Flow Conversion is defined as Adjusted Free Cash Flow divided by Adjusted Earnings. Management uses Adjusted Free Cash Flow Conversion as an indicator of our ability to convert earnings to cash.

Non-GAAP Financial Measures Definitions (Continued)

Transaction Adjusted Free Cash Flow & Transaction Adjusted Free Cash Flow Conversion

Management believes supplemental non-GAAP financial measures including Transaction-Adjusted Free Cash Flow and Transaction-Adjusted Free Cash Flow Conversion (each defined below) provide an integral view of information on the Company's underlying business performance during this period of transformational change. Management believes the Electronics Separation and Aramids Divestiture collectively represent a significant transformational change for the Company and separation-related transaction cost payments impact comparability to the Company's continuing operations. Management believes Transaction-Adjusted Free Cash Flow, which may be defined differently from other companies, is useful to investors, analysts and others to evaluate the Company's cash flow and financial performance, and it is an integral measure used in the Company's financial planning process. These non-GAAP financial measures are not intended to represent residual cash flow for discretionary expenditures since other non-discretionary expenditures, such as mandatory debt service requirements, are not deducted from the measure.

Transaction-Adjusted Free Cash Flow is defined as cash provided by/used for operating activities from continuing operations less capital expenditures and removing the impact of separation-related transaction costs and other payment and cash inflows/outflows that are unusual in nature and/or infrequent in occurrence that neither relate to the ordinary course of the Company's business nor reflect the Company's underlying business liquidity.

Transaction-Adjusted Free Cash Flow Conversion is defined as Transaction-Adjusted Free Cash Flow excluding separation-related transaction costs, divided by Adjusted Earnings.

Separation-related transaction costs and other payments include cash outflows directly associated with the Electronics Separation and the Aramids Divestiture. These costs include advisor and banking fees, payments related to establishing a new capital structure (including fees associated with interest rate swaps), capital expenditures required to facilitate physical asset separation, restructuring payments associated with senior leadership, and Future Reimbursable Indirect Costs, among other expenditures.

Future Reimbursable Indirect Costs are excluded from Adjusted Earnings and Operating EBITDA. To provide comparable data analysis, the Company has also adjusted payments associated with Future Reimbursable Indirect Costs within Separation-related transaction costs and other payments. This adjustment is intended to provide insight into the Company's underlying business performance. For the three and twelve months ended December 31, 2025, the Company adjusted $11 million and $70 million, respectively associated with Future Reimbursable Indirect Costs within Separation-related transaction costs and other payments.

For the twelve months ended December 31, 2025, the Company paid $123 million in fees associated with the settlement of interest rate swaps related to the 2048 notes, representing the allocated of the fair value of the swaps at the time of settlement, and $21 million in fees associated with the debt exchange. A total of $124 million and $144 million were reflected in Separation-related transaction costs and other payments for the three and twelve month periods ended December 31, 2025, respectively, these amounts related to achieving the post Electronics Separation capital structure.

Additionally, $4 million and $16 million were reflected in Separation-related transaction costs and other payments for the three and twelve month periods ended December 31, 2025, respectively, for expenditures incurred to complete the physical separation of shared locations.

Finally, $9 million of restructuring and other separation payments to senior leadership were reflected in Separation-related transaction costs and other payments for the three and twelve month periods ended December 31, 2025. These payments were reflected in other cash payments as they related to the establishment of the post-spin leadership structure.

Selected Financial Information and Non-GAAP Measures

DuPont de Nemours, Inc.

Selected Financial Information and Non-GAAP Measures

Net Sales

In millions	4Q25	4Q24	FY 2025	FY 2024
Net Sales	$ 1,693	$ 1,689	$ 6,849	$ 6,719

Non-GAAP Calculation of Operating EBITDA

In millions	4Q25	4Q24	FY 2025	FY 2024
(Loss) income from continuing operations, net of tax (GAAP)	$ (108)	$ (291)	$ 98	$ (96)
+ Provision for income taxes on continuing operations	42	92	102	213
(Loss) income from continuing operations before income taxes	$ (66)	$ (199)	$ 200	$ 117
+ Depreciation and amortization	159	163	647	635
- Interest income [1]	20	19	72	74
+ Interest expense [2]	61	84	311	365
- Non-operating pension/OPEB benefit credits	3	2	5	9
- Foreign exchange losses, net	(5)	16	(34)	(3)
+ Future reimbursable indirect costs	14	25	89	100
+ Remediation costs associated with divested businesses	4	3	12	14
- Adjustments for significant items charge	(255)	(356)	(412)	(380)
Operating EBITDA (non-GAAP)	$ 409	$ 395	$ 1,628	$ 1,531

1. Excludes accrued interest income earned on employee retention credits and interest income earned on cash held in escrow associated with Qnity financing.

2. Excludes interest rate swap basis amortization.

GAAP Income from Continuing Operations Margin

In millions	4Q25	4Q24	FY 2025	FY 2024
(Loss) income from continuing operations margin	(6.4)%	(17.2)%	1.4%	(1.4)%

Operating EBITDA Margin

In millions	4Q25	4Q24	FY 2025	FY 2024
Total operating EBITDA margin (non-GAAP) [1]	24.2%	23.4%	23.8%	22.8%

1. Operating EBITDA Margin is Operating EBITDA as a percentage of net sales.

Selected Financial Information and Non-GAAP Measures

DuPont de Nemours, Inc.

Adjusted EPS

Pretax Non-GAAP Adjustments to Net Income (Unaudited)

In millions	4Q25	4Q24	FY 2025	FY 2024
(Loss) income from continuing operations before income taxes (GAAP) [1]	$ (66)	$ (199)	$ 200	$ 117
Less: Significant items charge, before tax [1]	(255)	(356)	(412)	(380)
Less: Amortization of intangibles, before tax [1]	(71)	(76)	(291)	(294)
Less: Non-op pension / OPEB benefit credits, before tax [1]	3	2	5	9
Less: Future reimbursable indirect costs, before tax [1]	(14)	(25)	(89)	(100)
Less: Remediation costs associated with divested businesses [1]	(4)	(3)	(12)	(14)
Adjusted earnings, before tax (non-GAAP)	$ 275	$ 259	$ 999	$ 896

1. Impact on income from continuing operations before income taxes.

Non-GAAP Adjustments to Net Income (Unaudited)

In millions	4Q25	4Q24	FY 2025	FY 2024
Net (loss) income from continuing operations available to DuPont common stockholders (GAAP) [1]	$ (111)	$ (294)	$ 88	$ (98)
Less: Significant items charge, net of tax [1]	(238)	(380)	(316)	(400)
Less: Amortization of intangibles, net of tax [1]	(55)	(60)	(227)	(231)
Less: Non-op pension / OPEB benefit credits, net of tax [1]	3	2	5	7
Less: Future reimbursable indirect costs, net of tax [1]	(11)	(19)	(69)	(77)
Less: Remediation costs associated with divested businesses [1]	(3)	(2)	(9)	(10)
Adjusted earnings, net of tax (non-GAAP)	$ 193	$ 165	$ 704	$ 613

1. Impact on income from continuing operations available for DuPont common stockholders, net of tax. The income tax effect for each adjustment was calculated based on the statutory tax rate for the jurisdiction(s) in which the adjustment was taxable or deductible.

Non-GAAP Adjustments to Earnings Per Share (Unaudited)

In millions	4Q25	4Q24	FY 2025	FY 2024
(Loss) earnings per common share from continuing operations - diluted (GAAP) [1]	$ (0.27)	$ (0.70)	$ 0.21	$ (0.23)
Less: Significant items charge - diluted [1]	(0.57)	(0.90)	(0.76)	(0.95)
Less: Amortization of intangibles - diluted [1]	(0.13)	(0.14)	(0.54)	(0.55)
Less: Non-op pension / OPEB benefit credits - diluted [1]	0.01	-	0.01	0.02
Less: Future reimbursable indirect costs - diluted [1]	(0.03)	(0.04)	(0.16)	(0.18)
Less: Remediation costs associated with divested businesses [1]	(0.01)	(0.01)	(0.02)	(0.02)
Adjusted earnings per common share from continuing operations - diluted (non-GAAP)	$ 0.46	$ 0.39	$ 1.68	$ 1.45

1. Impact on earnings per common share from continuing operations - diluted.

Selected Financial Information and Non-GAAP Measures

DuPont de Nemours, Inc.

Segment Information (Unaudited)

Net Trade Revenue by Segment and Business or Major Product Line

In millions	4Q25	4Q24	FY 2025	FY 2024
Healthcare Technologies [1]	$ 437	$ 412	$ 1,758	$ 1,568
Water Technologies [1]	384	378	1,475	1,408
Healthcare & Water Technologies [1]	$ 821	$ 790	$ 3,233	$ 2,976
Industrial Technologies [1]	$ 483	$ 480	$ 2,003	$ 2,040
Building Technologies [1]	389	419	1,613	1,703
Diversified Industrials [1]	$ 872	$ 899	$ 3,616	$ 3,743
Total net sales by segment	**$ 1,693**	**$ 1,689**	**$ 6,849**	**$ 6,719**
U.S. & Canada	$ 839	$ 845	$ 3,415	$ 3,371
EMEA [2]	357	333	1,468	1,379
Asia Pacific [3]	419	431	1,640	1,647
Latin America	78	80	326	322
Total net sales by segment	**$ 1,693**	**$ 1,689**	**$ 6,849**	**$ 6,719**

1. Effective in the fourth quarter of 2025, as a result of the Electronics Separation, the Company realigned its management and reporting structure. This realignment resulted in a change in reportable segments in the fourth quarter of 2025 which changed the manner in which the Company reports financial results by segment. The information presented above has been recast for all periods presented to reflect the new two segment reporting structure.
2. Europe, Middle East and Africa.
3. Net sales attributed to China/Hong Kong, for the three months ended December 31, 2025 and 2024 were $184 million and $188 million, respectively, while for the twelve months ended December 31, 2025 and 2024 net sales attributed to China and Hong Kong were $708 million and $763 million, respectively.

Selected Financial Information and Non-GAAP Measures

DuPont de Nemours, Inc.
Segment Information (Unaudited)

Net Trade Revenue by Segment and Business or Major Product Line

	Three Months Ended December 31, 2025					
Percent change from prior year (Unaudited)	*Local Price & Product Mix*	*Volume*	*Total Organic*	*Currency*	*Portfolio / Other*	*Total*
Healthcare & Water Technologies	-%	3%	3%	1%	-%	4%
Diversified Industrials	-	(4)	(4)	1	-	(3)
Total	-%	(1)%	(1)%	1%	-%	-%
U.S. & Canada	2%	(2)%	-%	(1)%	-%	(1)%
EMEA [1]	(1)	3	2	5	-	7
Asia Pacific	(2)	-	(2)	(1)	-	(3)
Latin America	(2)	(1)	(3)	-	-	(3)
Total	-%	(1)%	(1)%	1%	-%	-%

	Twelve Months Ended December 31, 2025					
Percent change from prior year (Unaudited)	*Local Price & Product Mix*	*Volume*	*Total Organic*	*Currency*	*Portfolio / Other*	*Total*
Healthcare & Water Technologies	-%	7%	7%	1%	1%	9%
Diversified Industrials	(1)	(1)	(2)	-	(1)	(3)
Total	(1)%	3%	2%	-%	-%	2%
U.S. & Canada	-%	1%	1%	(1)%	1%	1%
EMEA [1]	(1)	4	3	2	1	6
Asia Pacific	(1)	5	4	-	(4)	-
Latin America	(2)	3	1	-	-	1
Total	(1)%	3%	2%	-%	-%	2%

1. Europe, Middle East and Africa.

Selected Financial Information and Non-GAAP Measures

DuPont de Nemours, Inc.
Segment Information (Unaudited)

Operating EBITDA

In millions	4Q25	4Q24	FY 2025	FY 2024
Healthcare & Water Technologies	$ 255	$ 246	$ 972	$ 844
Diversified Industrials	197	193	800	839
Corporate	(43)	(44)	(144)	(152)
Total operating EBITDA (non-GAAP)	$ 409	$ 395	$ 1,628	$ 1,531

Operating EBITDA Margin

In millions	4Q25	4Q24	FY 2025	FY 2024
Healthcare & Water Technologies	31.1%	31.1%	30.1%	28.4%
Diversified Industrials	22.6%	21.5%	22.1%	22.4%
Total operating EBITDA margin (non-GAAP) [1,2]	24.2%	23.4%	23.8%	22.8%

Significant Items (Pretax)

In millions	4Q25	4Q24	FY 2025	FY 2024
Healthcare & Water Technologies	$ (13)	$ (1)	$ (15)	$ (41)
Diversified Industrials	(9)	(10)	(19)	(55)
Corporate	(233)	(345)	(378)	(284)
Total significant items charge by segment (Pretax)	$ (255)	$ (356)	$ (412)	$ (380)

Depreciation and Amortization (Pretax)

In millions	4Q25	4Q24	FY 2025	FY 2024
Healthcare & Water Technologies	$ 92	$ 92	$ 370	$ 352
Diversified Industrials	63	62	244	245
Corporate	4	9	33	38
Total depreciation and amortization by segment (Pretax)	$ 159	$ 163	$ 647	$ 635

1. Operating EBITDA Margin is Operating EBITDA as a percentage of net sales.
2. Operating EBITDA Margin %'s for Corporate are not presented separately above as they are not meaningful; however, the results of Corporate are included in the total operating EBITDA margin %'s above

DUPONT™

Selected Financial Information and Non-GAAP Measures

DuPont de Nemours, Inc.
Adjusted Free Cash Flow Information (Unaudited)

Reconciliation of "Cash provided by operating activities - continuing operations" to Adjusted Free Cash Flow, Transaction-Adjusted Free Cash Flow and calculation of "Adjusted Free Cash Flow Conversion" and "Transaction-Adjusted Free Cash Flow Conversion"

In millions	4Q25	4Q24	YTD 2025	YTD 2024
Cash provided by operating activities - continuing operations (GAAP)	$ 87	$ 161	$ 560	$ 765
Capital expenditures	(87)	(71)	(333)	(285)
Adjusted free cash flow (non-GAAP) [1]	$ -	$ 90	$ 227	$ 480
Separation-related transaction cost and other payments [2]	228	29	462	107
Transaction-adjusted free cash flow (non-GAAP) [1]	$ 228	$ 119	$ 689	$ 587
Adjusted earnings (non-GAAP)	$ 193	$ 165	$ 704	$ 613
Adjusted free cash flow conversion (non-GAAP)	-%	55%	32%	78%
Transaction-adjusted free cash flow conversion (non-GAAP)	118%	72%	98%	96%

1. Calculated on a continuing operations basis for all periods presented.

2. Other payments for the year ended December 31, 2025 includes $144 million for interest rate swap settlements and debt exchange fees that were related to achieving the post-spin capital structure for new DuPont, $9 million related to restructuring related compensation cash payments for certain executive officers, $16 million of separation-related capital expenditures and $70 million for Future Reimbursable Indirect Costs (as defined in our Non-GAAP definitions).